China Digest: Biozon, Morewis and Surreal raise fresh capital to expand operations
Photo by Henk Vrieselaar on Unsplash
March 3, 2021
Clinical mass spectrometry specialist Biozon, industrial software developer Morewis, and synthetic media startup Surreal have secured new financing to expand operations.
Biozon nets $46m Series C
Clinical mass spectrometry specialist Biozon has raked in 300 million yuan ($46 million) in its Series C round of financing led by CITIC Private Equity Funds Management (CPE), a leading alternative asset manager co-launched in 2008 by state-backed CITIC Group.
The latest round also saw participation from healthcare investment firm Sherpa Healthcare Partners and Huagai Capital, an over 15 billion yuan ($2.3 billion) fund that focuses on healthcare, TMT, and culture, per a company statement on Wednesday.
China Digest: BangEr, Cothera, MAKE ESSENSE in funding news Premium
Chinese specialized hospital chain operator BangEr Orthopedic, anti-tumour drug developer Cothera Bioscience, and men’s skincare brand MAKE ESSENSE have raked in new financing to expand operations.
Continue reading this story with a subscription to DealStreetAsia.
Contact us for corporate subscriptions at subs@dealstreetasia.com.
Sign up for our newsletter - The Daily Brief Opt out of receiving The Daily Brief in your inbox everyday
REGISTER stories left placeholder You have one free story left this month. You have stories left placeholder free stories left this month. This is your last free story of the month.
VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China
News provided by
Share this article
SHANGHAI, Jan. 9, 2021 /PRNewswire/
VISEN Pharmaceuticals, a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China, announced today the closing of a $150 million Series B financing.
The round was led by Sequoia China with participation from OrbiMed, Sherpa Healthcare Partners, Cormorant, HBM Healthcare Investments, Pivotal bioVenture Partners China, Logos Capital, and CDG Capital, as well as all of the existing investors, including Ascendis Pharma A/S, Vivo Capital and Sofinnova Investments. Proceeds of the Series B financing will be used to accelerate the clinical development of the potential best-in-class portfolio drug candidates and to build a strong foundation for commer